$218.11 +2.32 (%) Synageva BioPharma Corp - NASDAQ

May. 22, 2015 | 04:00 PM

Partner Headlines

  1. Intercept's NASH Trial Design Irks Investors

    IBD | May. 19, 2015 | 11:36AM EST
  2. Alexion Acquiring Synageva For $8.4 Billion

    GuruFocus | May. 9, 2015 | 18:13PM EST
  3. Benzinga's Volume Movers

    Benzinga | May. 7, 2015 | 12:20PM EST
  4. Benzinga's Top Downgrades

    Benzinga | May. 7, 2015 | 09:49AM EST
  5. Alexion To Acquire Synageva

    IBD | May. 6, 2015 | 18:56PM EST
  6. Wednesday Pre-Market Insights: GEVA, BRDR, MGI, NDLS, ZU

    GuruFocus | May. 6, 2015 | 18:20PM EST
  7. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD | May. 6, 2015 | 18:20PM EST
  8. Benzinga's M&A Chatter for Wednesday May 6, 2015

    Benzinga | May. 6, 2015 | 18:17PM EST
  9. Stocks Fall On Yellen Comment; Tesla Firm Ahead Of Earnings

    IBD | May. 6, 2015 | 13:23PM EST
  10. Stocks Down At Midday; Apple Flirts With Sell Signal

    IBD | May. 6, 2015 | 12:01PM EST
  11. Alexion Buying Synageva For $230 A Share; Stock Slips

    IBD | May. 6, 2015 | 10:48AM EST
  12. Benzinga's Volume Movers

    Benzinga | May. 6, 2015 | 10:40AM EST
  13. Synageva Shares Soar 116% On Buyout Deal With Alexion Pharmaceuticals

    Benzinga | May. 6, 2015 | 10:30AM EST
  14. Stocks Fade From Higher Open; Synageva Surges On Buyout News

    IBD | May. 6, 2015 | 10:28AM EST
  15. Morning Market Losers

    Benzinga | May. 6, 2015 | 09:56AM EST
  16. Morning Market Gainers

    Benzinga | May. 6, 2015 | 09:45AM EST
  17. Benzinga's Top #PreMarket Losers

    Benzinga | May. 6, 2015 | 08:23AM EST
  18. Benzinga's Top #PreMarket Gainers

    Benzinga | May. 6, 2015 | 08:14AM EST
  19. Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma

    Benzinga | Feb. 27, 2015 | 10:34AM EST
  20. Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

    Benzinga | Jan. 26, 2015 | 07:31AM EST
  21. Clear Channel Outdoor, Oasis Petroleum And Other Insiders Have Been Buying

    Benzinga | Jan. 12, 2015 | 14:33PM EST
  22. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  23. 4 More Biotech Secondaries Investors Are Watching

    Benzinga | Jan. 7, 2015 | 12:50PM EST
  24. Benzinga's Volume Movers

    Benzinga | Jan. 7, 2015 | 10:23AM EST
  25. 4 Biotech Secondary Offerings Traders Are Watching

    Benzinga | Jan. 6, 2015 | 13:05PM EST
  26. Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa

    Benzinga | Dec. 2, 2014 | 09:04AM EST
  27. Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting

    Benzinga | Oct. 23, 2014 | 16:18PM EST
  28. Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

    Benzinga | Jul. 2, 2014 | 06:47AM EST
  29. Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

    Benzinga | Jul. 1, 2014 | 15:09PM EST
  30. Mid-Day Market Update: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

    Benzinga | Jul. 1, 2014 | 12:22PM EST
  31. Markets Surge; GM June Sales Rise 1%

    Benzinga | Jul. 1, 2014 | 10:23AM EST
  32. Morning Market Losers

    Benzinga | Jul. 1, 2014 | 09:46AM EST
  33. SYNAGEVA BIOPHARMA

    IBD | Jun. 30, 2014 | 18:52PM EST
  34. Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

    Benzinga | Jun. 30, 2014 | 16:03PM EST
  35. UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

    Benzinga | Apr. 1, 2014 | 09:29AM EST
  36. UPDATE: Synageva Biopharma™ Announces 2M Share Proposed Public Offering of Its Common Stock

    Benzinga | Mar. 4, 2014 | 16:32PM EST
  37. Synageva BioPharma Completes Target Enrollment in Phase 3 ARISE Trial

    Benzinga | Dec. 2, 2013 | 16:09PM EST
  38. Benzinga's Top Initiations

    Benzinga | Nov. 15, 2013 | 08:30AM EST
  39. UPDATE: Goldman Sachs initiates on Synageva Following Positive Phase II Data On Sebelipase

    Benzinga | Nov. 15, 2013 | 07:47AM EST
  40. UPDATE: Leerink Swann Downgrades Synageva BioPharma Corp. on Lack of NT News Flow, Market Opportunity Visibility

    Benzinga | Oct. 22, 2013 | 10:44AM EST
  41. UPDATE: Wedbush Downgrades Synageva BioPharma on Valuation

    Benzinga | Oct. 7, 2013 | 10:55AM EST
  42. Benzinga's Volume Movers

    Benzinga | Sep. 25, 2013 | 10:26AM EST
  43. Synageva BioPharma Prices 2.75M Share Offering at $56.63/Share

    Benzinga | Sep. 24, 2013 | 19:48PM EST
  44. Synageva BioPharma Corp (GEVA) SVP, CFO Carsten Boess sells 9,927 Shares

    GuruFocus | Jan. 22, 2013 | 07:06AM EST
  45. UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Synageva BioPharma Corp.

    Benzinga | Jan. 4, 2013 | 06:59AM EST
  46. Synageva Prices 2.15M Share Public Offering at $47.53/Share

    Benzinga | Jan. 3, 2013 | 12:43PM EST
  47. UPDATE: Piper Jaffray Downgrades Synageva to Neutral on Lack of Near-Term Catalysts

    Benzinga | Jan. 3, 2013 | 02:30AM EST
  48. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 60,000 Shares

    GuruFocus | Dec. 17, 2012 | 13:37PM EST
  49. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 35,000 Shares

    GuruFocus | Dec. 6, 2012 | 11:37AM EST
  50. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 35,000 Shares

    GuruFocus | Dec. 4, 2012 | 11:38AM EST
Trading Center